Clinical trial
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC…
NCT02514447 · G1 Therapeutics, Inc., Industry · Completed
Key facts
| NCT number | NCT02514447 |
|---|---|
| Title | Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy |
| Official title | Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy |
| Lead sponsor | G1 Therapeutics, Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Trilaciclib, Placebo, Topotecan |
| Enrollment | 123 |
| Start date | Oct 5, 2015 |
| Primary completion | Sep 28, 2018 |
| Completion | Oct 4, 2021 |
| First posted | Aug 3, 2015 |
| Last update posted | Sep 25, 2025 |
| Countries | Belgium, Bosnia and Herzegovina, Croatia, North Macedonia, Serbia, Slovakia, Slovenia, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: